| Hoffgen KS, Dabel J, Konken CP, Depke DA, Hermann S, Dorner W, Schelhaas S, Schafers M, Mootz HD. Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo. Nucl Med Biol 2024;136-137: 108937. Abstract
|
| Landau F, Hermann S, Schelhaas S, Schafers M, Niemann S, Faust A. 18F-labelled gentiobiose as potential PET-radiotracer for specific bacterial imaging: precursor synthesis, radiolabelling and in vitro evaluation. Nuklearmedizin 2024Abstract
|
| Margeta R, Schelhaas S, Hermann S, Schafers M, Niemann S, Faust A. A novel radiolabelled salmochelin derivative for bacteria-specific PET imaging: synthesis, radiolabelling and evaluation. Chem Commun (Camb) 2024Abstract
|
| Konken CP, Hessling K, Thale I, Schelhaas S, Dabel J, Maskri S, Bulk E, Budde T, Koch O, Schwab A, Schafers M, Wunsch B. Imaging of the calcium activated potassium channel 31 (KCa 31) in vivo using a senicapoc-derived positron emission tomography tracer. Arch Pharm (Weinheim) 2022: e2200388. Abstract
|
| Schelhaas S, Frohwein LJ, Wachsmuth L, Hermann S, Faber C, Schafers KP, Jacobs AH. Voxel-Based Analysis of the Relation of 3'-Deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) PET and Diffusion-Weighted (DW) MR Signals in Subcutaneous Tumor Xenografts Does Not Reveal a Direct Spatial Relation of These Two Parameters. Mol Imaging Biol 2022;24: 359-364. Abstract
|
| Foray C, Barca C, Backhaus P, Schelhaas S, Winkeler A, Viel T, Schafers M, Grauer O, Jacobs AH, Zinnhardt B. Multimodal Molecular Imaging of the Tumour Microenvironment. Adv Exp Med Biol 2020;1225: 71-87. Abstract
|
| Rezaei M, Martins Cavaco AC, Stehling M, Nottebaum A, Brockhaus K, Caliandro MF, Schelhaas S, Schmalbein F, Vestweber D, Eble JA. Extracellular Vesicle Transfer from Endothelial Cells Drives VE-Cadherin Expression in Breast Cancer Cells, Thereby Causing Heterotypic Cell Contacts. Cancers (Basel) 2020;12Abstract
|
| Schelhaas S. Applications of Small Animal PET. Recent Results Cancer Res 2020;216: 493-507. Abstract
|
| Soria-Martinez L, Bauer S, Giesler M, Schelhaas S, Materlik J, Janus K, Pierzyna P, Becker M, Snyder NL, Hartmann L, Schelhaas M. Prophylactic Antiviral Activity of Sulfated Glycomimetic Oligomers and Polymers. J Am Chem Soc 2020;142: 5252-5265. Abstract
|
| Kailayangiri S, Altvater B, Lesch S, Balbach S, Gottlich C, Kuhnemundt J, Mikesch J-H, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Muller I, Walles H, Hartmann W, Rossig C. EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. Mol Ther 2019;27: 933-946. Abstract
|
| Schelhaas S, Heinzmann K, Honess DJ, Smith D-M, Keen H, Heskamp S, Witney TH, Besret L, Doblas S, Griffiths JR, Aboagye EO, Jacobs AH. 3'-Deoxy-3'-[(18)F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models. Mol Imaging Biol 2018;20: 194-199. Abstract
|
| Schelhaas S, Wachsmuth L, Hermann S, Rieder N, Heller A, Heinzmann K, Honess DJ, Smith D-M, Fricke IB, Just N, Doblas S, Sinkus R, Doring C, Schafers KP, Griffiths JR, Faber C, Schneider R, Aboagye EO, Jacobs AH. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-(18)F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model. J Nucl Med 2018;59: 1063-1069. Abstract
|
| Fricke IB, Schelhaas S, Zinnhardt B, Viel T, Hermann S, Couillard-Despres S, Jacobs AH. In vivo bioluminescence imaging of neurogenesis - the role of the blood brain barrier in an experimental model of Parkinson's disease. Eur J Neurosci 2017;45: 975-986. Abstract
|
| Heinzmann K, Honess DJ, Lewis DY, Smith D-M, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM. Correction to: The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. EJNMMI Res 2017;7: 99. Abstract
|
| Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH. Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review. Theranostics 2017;7: 40-50. Abstract
|
| Waerzeggers Y Zinnhardt B Winkeler A Monfared P Schelhaas S Viel T Jacobs AH. Imaging in Neurooncology. In: Kiessling F., Pichler B. Small Animal Imaging 2017;Springer, Cham: 689-725. Abstract
|
| Zinnhardt B, Pigeon H, Theze B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schafers M, Winkeler A, Jacobs AH. Combined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake. Cancer Res 2017;77: 1831-1841. Abstract
|
| Heinzmann K, Honess DJ, Lewis DY, Smith D-M, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM. The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. EJNMMI Res 2016;6: 63. Abstract
|
| Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology 2016: e1250050. Abstract
|
| Schelhaas S, Held A, Baumer N, Viel T, Hermann S, Muller-Tidow C, Jacobs AH. Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy. Cancer Res 2016;76: 7089-7095. Abstract
|
| Schelhaas S, Held A, Wachsmuth L, Hermann S, Honess DJ, Heinzmann K, Smith D-M, Griffiths JR, Faber C, Jacobs AH. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer. Cancer Res 2016;76: 7096-7105. Abstract
|
| Baumer S, Baumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Muller-Tidow C. Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. Clin Cancer Res 2015;21: 1383-1394. Abstract
|
| Bulk E, Ay A-S, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Marra A, Hillejan L, Jacobs AH, Klein H-U, Dugas M, Berdel WE, Muller-Tidow C, Schwab A. Epigenetic dysregulation of KCa 31 channels induces poor prognosis in lung cancer. Int J Cancer 2015;137: 1306-1317. Abstract
|
| Fahrlander E, Schelhaas S, Jacobs AH, Langer K. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology 2015;26: 145103. Abstract
|
| Schelhaas S, Wachsmuth L, Viel T, Honess DJ, Heinzmann K, Smith D-M, Hermann S, Wagner S, Kuhlmann MT, Muller-Tidow C, Kopka K, Schober O, Schafers M, Schneider R, Aboagye EO, Griffiths J, Faber C, Jacobs AH. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-18F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. J Nucl Med 2014;55: 983-988. Abstract
|
| Steingräber AK, Schelhaas S, Faust A, Jacobs AH, Schäfers M, Goerge T. Molecular imaging reveals time course of MMP activity in acute cutaneous vasculitis in vivo. Exp Dermatol 2013;22: 730-735. Abstract
|
| Viel T, Monfared P, Schelhaas S, Fricke IB, Kuhlmann MT, Fraefel C, Jacobs AH. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology. Mol Ther 2013;21: 570-579. Abstract
|
| Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, Faber C, Kopka K, Schafers M, Jacobs AH. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One 2013;8: e67911. Abstract
|
| Waerzeggers Y, Viel T, Schäfers S, Wagner S, Faust A, Riemann B, Kopka K, Schober O, Schäfers K, Jacobs AH. Positron Emission Tomography (PET)-based Molecular Imaging. Part 5 - Imaging Technologies in Animal Tumor Models: Measuring Brain Tumor Growth and Metabolism 2013;Neuromethods; 77: 301-327.
|
